Accord Adds To Crowded EU Trastuzumab Market

First China-Developed mAb To Launch In EU

 
• By Dean Rudge

Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.

Europe_Map_Connection
The market for trastuzumab in Europe continues to grow • Source: Shutterstock

More from Biosimilars

More from Products